ElixirTrials exits stealth with clinical trial network for community hospitals

ElixirTrials launched Tuesday from stealth with software and a site network designed to help hospitals run sponsor-grade clinical trials where patients already receive care. The Chicago company says its model could speed study activation for life sciences firms while expanding access beyond major research centers.

Why it matters: - Clinical trials are still concentrated at a relatively small number of research institutions, leaving many eligible patients without easy access. - ElixirTrials is trying to move trial infrastructure into community hospitals and health systems, where most patients already get care. - The model could lower the cost and complexity of launching studies for life sciences companies. - Hospitals could add research capabilities without spending years building programs from scratch.

What happened: - ElixirTrials emerged from stealth on July 20, 2026, in Chicago. - The company launched an intelligent operating system called Cauldron and a national research site network. - ElixirTrials says the platform is designed to help hospitals deliver sponsor-grade clinical research and simplify activation for sponsors. - The company was co-founded by Heather Grey, a former clinical trials executive at Tempus and Omega Healthcare, and Noah Dolev, Ph.D., an artificial intelligence researcher and technology entrepreneur. - Grey is chief executive officer, and Dolev is chief technology officer.

The details: - Cauldron is built for distributed clinical research. - The system standardizes workflows across hospitals, studies and sponsors. - ElixirTrials says Cauldron captures operational knowledge from each study and reuses it across the network. - The platform is powered by artificial intelligence. - Physicians, research coordinators and regulatory professionals remain in control of clinical decisions. - The company provides technology, an operating framework, regulatory expertise and sponsor connectivity. - ElixirTrials says healthcare organizations can launch and operate trials as part of everyday patient care rather than building separate research infrastructure. - Sponsors would use a single commercial relationship to access the network instead of contracting with many independent sites. - The company says that approach can shorten the path from protocol approval to first patient enrolled. - ElixirTrials is already working with leading healthcare organizations. - The company is preparing to activate its first network of health system partners. - Additional partnership announcements are expected. - Grey said the goal is to make clinical research part of everyday healthcare. - Dolev said Cauldron is meant to serve as the institutional memory for clinical research. - ElixirTrials included links to LinkedIn, Instagram and Facebook.

Between the lines: - The company is betting that clinical research will scale faster if it is embedded in existing care settings instead of routed through specialized centers. - The network model also suggests a push to make trial activation feel more like a standardized enterprise service than a site-by-site sourcing exercise. - The AI pitch is not just automation. ElixirTrials is framing software as a way to preserve and reuse operational know-how across studies.

What's next: - ElixirTrials plans to activate its inaugural network of health system partners. - More partnership announcements are forthcoming. - The company will need to prove that its standardized model can work across different hospital systems and study types while maintaining compliance and speed.

The bottom line: - ElixirTrials wants to make clinical trials easier to launch, easier to scale and available closer to home.